• 1
    Andersen BL, Anderson B, DeProsse C. Controlled prospective longitudinal study of women with cancer: I. Sexual functioning outcomes. J Consult Clin Psychol. 1989; 57: 683-691.
  • 2
    Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2003; 56: 937-949.
  • 3
    Carmack-Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol. 2004; 22: 881-889.
  • 4
    Lindau ST, Gavrilova N, Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol. 2007; 106: 413-418.
  • 5
    Jeffery D, Tzeng J, Keefe F, et al. Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee. Cancer. 2009; 115: 1142-1153.
  • 6
    Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26: 191-208.
  • 7
    Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scandia. 2002; 81: 443-450.
  • 8
    Levin AO, Carpenter KM, Fowler JM, Brothers BM, Andersen BL, Maxwell GL. Sexual morbidity associated with poorer psychological adjustment among gynecological cancer survivors. Int J Gynecol Cancer. 2010; 20: 461-470.
  • 9
    Adelusi B. Coital function after radiotherapy for carcinoma of the cervix uteri. Br J Obstet Gynaecol. 1980; 87: 821-823.
  • 10
    Flay LD, Matthews JHL. The effects of radiotherapy and surgery on the sexual function of women treated for cervical cancer. Int J Radiat Oncol Biol Phys. 1995; 31: 399-404.
  • 11
    Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther. 2003; 29: 39-46.
  • 12
    Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005; 31: 1-20.
  • 13
    Likes WM, Stegbauer C, Hathaway D, Brown C, Tillmanns T. Use of the female sexual function index in women with vulvar intraepithelial neoplasia. J Sex Marital Ther. 2006; 32: 255-266.
  • 14
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Revised 4th ed (DMS-IV-TR). Washington, DC: American Psychiatric Association; 2000.
  • 15
    World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Geneva, Switzerland: World Health Organization; 1992.
  • 16
    Carter J, Applegarth L, Josephs L, Grill E, Baser RE, Rosenwaks Z. A cross-sectional cohort study of infertile women awaiting oocyte donation: the emotional, sexual, and quality-of-life impact [serial online]. Fertil Steril. 2011; 95: 711-716.e1.
  • 17
    Carter J, Chi DS, Brown CL, et al. Cancer-related infertility in survivorship. Int J Gynecol Cancer. 2010; 20: 2-8.
  • 18
    Carter J, Raviv L, Applegarth L, et al. A cross-sectional study of the psychosexual impact of cancer-related infertility in women: third-party reproductive assistance. J Cancer Surviv. 2010; 4: 236-246.
  • 19
    Carter J, Sonoda Y, Baser RE, et al. A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol. 2010; 119: 358-365.
  • 20
    Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005; 23: 7428-7436.
  • 21
    Schroder MA, Mell LK, Hurteau JA, et al. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys. 2005; 61: 1078-1086.
  • 22
    Tsai TY, Chen SY, Tsai MH, Ho CM, Su YL. Factors related to sexual dysfunction in patients with cervical cancer [article in Chinese]. Hu Li Za Zhi. 2009; 56: 37-46.
  • 23
    Schover LR, Jenkins R, Sui D, Adams JH, Marion MS, Jackson KE. Randomized trial of peer counseling on reproductive health in African American breast cancer survivors. J Clin Oncol. 2006; 24: 1620-1626.
  • 24
    Speer JJ, Hillenberg B, Sugrue DP, et al. Study of sexual functioning determinants in breast cancer survivors. Breast J. 2005; 11: 440-447.
  • 25
    Jayne D, Brown J, Thorpe H, Walker J, Quirke P, Guillou P. Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg. 2005; 92: 1124-1132.
  • 26
    Hendren SK, O'Connor BI, Liu M, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg. 2005; 242: 212.
  • 27
    Bhatt A, Nandipati K, Dhar N, et al. Neurovascular preservation in orthotopic cystectomy: impact on female sexual function. Urology. 2006; 67: 742-745.
  • 28
    Thirlaway K, Fallowfield L, Cuzick J. The sexual activity questionnaire: a measure of women's sexual functioning. Qual Life Res. 1996; 5: 81-90.
  • 29
    Jensen PT, Klee MC, Thranov I, Groenvold M. Validation of a questionnaire for self assessment of sexual function and vaginal changes after gynaecological cancer. Psychooncology. 2004; 13: 577-592.
  • 30
    Bransfield DD, Horiot JC, Nabid A. Development of a scale for assessing sexual function after treatment for gynecologic cancer. J Psychosoc Oncol. 1984; 2: 3-19.
  • 31
    Monk BJ, Huang HQ, Cella D, Long HJ. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 23: 4617-4625.
  • 32
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
  • 33
    Ware JE Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34: 220-233.
  • 34
    Ware JE Jr, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12 Health Survey. Quality Lincoln, RI: Metric Incorporated; 2002.
  • 35
    Devins GM, Orme CM, Costello CG, et al. Measuring depressive symptoms in illness populations: psychometric properties of the Center for Epidemiologic Studies Depression (CES-D) scale. Psychol Health. 1988; 2: 139-156.
  • 36
    Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med. 1979; 41: 209-218.
  • 37
    Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life (HRQL) and tamoxifen in breast cancer prevention. J Clin Oncol. 1999; 17: 2659-2669.
  • 38
    Sharpley C, Cross DG. A psychometric evaluation of the Spanier Dyadic Adjustment Scale. J Marriage Fam. 1982; 44: 739-741.
  • 39
    Hunsley J, Pinsent C, Lefebvre M, James-Tanner S, Vito D. Construct validity of the short forms of the Dyadic Adjustment Scale. Fam Rel. 1995; 44: 231-237.
  • 40
    Wenzel L, Dogan-Ates A, Habbal R, et al. Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr. 2005; 34: 94-98.
  • 41
    Meyer-Bahlburg H, Dolezal C. The Female Sexual Function Index: a methodological critique and suggestions for improvement. J Sex Marital Ther. 2007; 33: 217-224.
  • 42
    Brotto LA. The Female Sexual Function Index: a methodological critique and suggestions for improvement [letter]. J Sex Marital Ther. 2009; 35: 161-163.
  • 43
    Hakstian AR, Whalen TE. A k-sample significance test for independent alpha coefficients. Psychometrika. 1976; 41: 219-231.
  • 44
    Flynn KE, Jeffery DD, Keefe FJ, et al. Sexual functioning along the cancer continuum: focus group results from the Patient Reported Outcomes Measurement Information System (PROMIS). Psychooncology. 2011; 20: 378-386.